Related references
Note: Only part of the references are listed.Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer's disease
S. -H. Han et al.
ACTA NEUROLOGICA SCANDINAVICA (2017)
Alzheimer's Disease: Targeting the Cholinergic System
Talita H. Ferreira-Vieira et al.
CURRENT NEUROPHARMACOLOGY (2016)
Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial
Akira Homma et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease
Nathan Herrmann et al.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (2016)
ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension
Laura M. Gault et al.
ALZHEIMERS RESEARCH & THERAPY (2016)
Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase
Edeltraut Kroeger et al.
ANNALS OF PHARMACOTHERAPY (2015)
Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles
Eve Tang et al.
BMC MEDICINE (2015)
The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease
William James Deardorff et al.
DRUGS & AGING (2015)
Cholinesterase Inhibitor Discontinuation in Patients With Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Trials
Jordana O'Regan et al.
JOURNAL OF CLINICAL PSYCHIATRY (2015)
Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada
Thibault B. Ali et al.
PLOS ONE (2015)
Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial
Hossein Pakdaman et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA (2015)
Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease
Gerard J. Marek et al.
ALZHEIMERS & DEMENTIA (2014)
Cardiovascular Effects of Drugs Used to Treat Alzheimer's Disease
Laurence Guy Howes
DRUG SAFETY (2014)
Rivastigmine Transdermal Patch 13.3 mg/24 h: A Review of Its Use in the Management of Mild to Moderate Alzheimer's Dementia
James E. Frampton
DRUGS & AGING (2014)
Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease
David Prvulovic et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2014)
Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer's Disease
Muriel Noetzli et al.
CLINICAL PHARMACOKINETICS (2013)
Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study
Serge Gauthier et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Acetylcholinesterase Inhibitors: Pharmacology and Toxicology
Mirjana B. Colovic et al.
CURRENT NEUROPHARMACOLOGY (2013)
Association between behavioral and psychological symptoms and psychotropic drug use among old people with cognitive impairment living in geriatric care settings
Maria Gustafsson et al.
INTERNATIONAL PSYCHOGERIATRICS (2013)
Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012
Nathan Herrmann et al.
Alzheimers Research & Therapy (2013)
Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia
Howard Chertkow et al.
ALZHEIMERS RESEARCH & THERAPY (2013)
Subgroup Analysis of US and Non-US Patients in a Global Study of High-Dose Donepezil (23 mg) in Moderate and Severe Alzheimer's Disease
Stephen Salloway et al.
AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS (2012)
Efficacy and Safety of Donepezil 23 mg versus Donepezil 10 mg for Moderate-to-Severe Alzheimer's Disease: A Subgroup Analysis in Patients Already Taking or Not Taking Concomitant Memantine
Rachelle S. Doody et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2012)
Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm2) in Alzheimer's Disease
Jeffrey Cummings et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2012)
Cardiac Safety of Donepezil in Elderly Patients with Alzheimer Disease
Ahmet Turan Isik et al.
INTERNAL MEDICINE (2012)
Withdrawal syndrome after donepezil cessation in a patient with dementia
Leszek Bidzan et al.
NEUROLOGICAL SCIENCES (2012)
Higher-Dose (23 mg/day) Donepezil Formulation for the Treatment of Patients with Moderate-to-Severe Alzheimer's Disease
Daniel D. Christensen
POSTGRADUATE MEDICINE (2012)
Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions
Peter Pregelj
PSYCHOGERIATRICS (2012)
Pharmacokinetic Comparison of Orally Disintegrating and Conventional Donepezil Formulations in Healthy Korean Male Subjects: A Single-Dose, Randomized, Open-Label, 2-Sequence, 2-Period Crossover Study
Kyoung-Ah Kim et al.
CLINICAL THERAPEUTICS (2011)
Dementia Medications and Risk of Falls, Syncope, and Related Adverse Events: Meta-Analysis of Randomized Controlled Trials
Dae Hyun Kim et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2011)
Rivastigmine Transdermal Patch Skin Tolerability Results of a 1-Year Clinical Trial in Patients with Mild-to-Moderate Alzheimer's Disease
Jeffrey L. Cummings et al.
CLINICAL DRUG INVESTIGATION (2010)
Effectiveness and Tolerability of High-Dose (23 mg/d) Versus Standard-Dose (10 mg/d) Donepezil in Moderate to Severe Alzheimer's Disease: A 24-Week, Randomized, Double-Blind Study
Martin R. Farlow et al.
CLINICAL THERAPEUTICS (2010)
Syncope and Its Consequences in Patients With Dementia Receiving Cholinesterase Inhibitors A Population-Based Cohort Study
Sudeep S. Gill et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials
Bengt Winblad et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Safety and Tolerability of Donepezil, Rivastigmine and Galantamine for Patients with Alzheimer's Disease: Systematic Review of the 'Real-World' Evidence
I. A. Lockhart et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2009)
Cholinesterase Inhibitors and Incidence of Bradycardia in Patients with Dementia in the Veterans Affairs New England Healthcare System
Rohini K. Hernandez et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2009)
Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease
Alberto Pilotto et al.
NEUROLOGY (2009)
Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan
Motohiro Nozawa et al.
PSYCHOGERIATRICS (2009)
Safety and tolerability of donepezil at doses up to 20 mg/day - Results from a pilot study in patients with Alzheimer's disease
Rachelle S. Doody et al.
DRUGS & AGING (2008)
Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients
G. Lefevre et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
A population-based study of cholinesterase inhibitor use for dementia
Nathan Herrmann et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2007)
Donepezil preserves cognition and global function in patients with severe Alzheimer disease
S. E. Black et al.
NEUROLOGY (2007)
Drug interactions with cholinesterase inhibitors - An analysis of the French Pharmacovigilance Database and a comparison of two national drug formularies (Vidal, British National Formulary)
Neda Tavassoli et al.
DRUG SAFETY (2007)
Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease
Rafael Blesa et al.
PHARMACOGENETICS AND GENOMICS (2006)
Donepezil in patients with severe Alzheimer's disease:: double-blind, parallel-group, placebo-controlled study
B Winblad et al.
LANCET (2006)
Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease
R Bullock et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Cholinesterase inhibitors for Alzheimer's disease
J Birks
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2006)
3-year study of donepezil therapy in Alzheimer's disease: Effects of early and continuous therapy
B. Winblad et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2006)
Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles
MF Eskander et al.
BRAIN RESEARCH (2005)
A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs
SS Gill et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease
H Brodaty et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2005)
Cholinesterase inhibitors for the treatment of Alzheimer's disease: Getting on and staying on
GT Grossberg
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2003)
Clinical pharmacokinetics of galantamine
MR Farlow
CLINICAL PHARMACOKINETICS (2003)
Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease
JL Cummings et al.
JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY (2001)
Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease
RS Doody et al.
ARCHIVES OF NEUROLOGY (2001)
Share Paper
